• 1
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22:147991.
  • 2
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25:226794.
  • 3
    Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007; 89:34953.
  • 4
    Ali T, Jay RH. Spontaneous femoral shaft fracture after long-term alendronate. Age Ageing. 2009; 38:6256.
  • 5
    Bunning RD, Rentfro RJ, Jelinek JS. Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series. PM R. 2010; 2:7680.
  • 6
    Bush L, Chew F. Subtrochanteric femoral insufficiency fracture following bisphosphonate therapy for osseous metastases. Radiol Case Rep. [Internet]. 2008 [cited 2013 Jun 9]; 3(4):232. Available from
  • 7
    Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009; 91:255661.
  • 8
    Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2009; 468:19916.
  • 9
    Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007; 13:4859.
  • 10
    Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med. 2010; 362:18489.
  • 11
    Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone. 2011; 48:96671.
  • 12
    Grasko JM, Herrmann RP, Vasikaran SD. Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates. J Oral Maxillofac Surg. 2009; 67:6459.
  • 13
    Husada G, Libberecht K, Peeters T, Populaire J. Bilateral mid-diaphyseal femoral stress fractures in the elderly. Eur J Trauma. 2005; 31(1):6871.
  • 14
    Isaacs JD, Shidiak L, Harris IA, Szomor ZL. Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res. 2010; 468:338492.
  • 15
    Koh JS, Goh SK, Png MA, Kwek EB, Howe TS. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?. J Orthop Trauma. 2010; 24:7581.
  • 16
    Lee JK. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. Int J Rheum Dis. 2009; 12:14954.
  • 17
    Napoli N, Novack D, Armamento-Villareal R. Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. Osteoporos Int. 2010; 21:7058.
  • 18
    Chang ST, Tenforde AS, Grimsrud CD, O'Ryan FS, Gonzalez JR, Baer DM, Chandra M, Lo JC. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone. 2012; 51:5247.
  • 19
    Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am. 2011; 93:123542.
  • 20
    Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury. 2008; 39:22431.
  • 21
    Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009; 20:135362.
  • 22
    Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22:34650.
  • 23
    Mohan PC, Howe TS, Koh JS, Png MA. Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy. Eur Radiol. 2013; 23:2227.
  • 24
    Demiralp B, Ilgan S, Ozgur Karacalioglu A, Cicek EI, Yildrim D, Erler K. Bilateral femoral insufficiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg. 2007; 127:597601.
  • 25
    Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006; 61:313.
  • 26
    Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009; 24:173640.
  • 27
    Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010; 47:16980.
  • 28
    Ing-Lorenzini K, Desmeules J, Plachta O. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf. 2009; 32:77585.
  • 29
    Somford MP, Geurts GF, den Teuling JW, Thomassen BJ, Draijer WF. Long-term alendronate use not without consequences?. Int J Rheumatol. 2009; 2009:253432.
  • 30
    Donnelly E, Saleh A, Unnanuntana A, Lane JM. Atypical femoral fractures: epidemiology, etiology, and patient management. Curr Opin Support Palliat Care. 2012; 6:34854.
  • 31
    Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int. 2011; 22:37390.
  • 32
    Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009; 24:1095102.
  • 33
    Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95:525865.
  • 34
    Abrahamsen B. Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low. Evid Based Med. 2011; 16:1689.
  • 35
    Hsiao FY, Huang WF, Chen YM, Wen YW, Kao YH, Chen LK, Tsai YW. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. Clin Ther. 2011; 33:165967.
  • 36
    Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011; 26:9931001.
  • 37
    Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, Cosman F. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int. 2010; 21:399408.
  • 38
    Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int. 2011; 22:9931001.
  • 39
    Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011; 305:7839.
  • 40
    Beaudouin-Bazire C, Dalmas N, Bourgeois J, Babinet A, Anract P, Chantelot C, Farizon F, Chopin F, Briot K, Roux C, Cortet B, Thomas T. Real frequency of ordinary and atypical sub-trochanteric and diaphyseal fractures in France based on X-rays and medical file analysis. Joint Bone Spine. 2013 Mar; 80(2):2015.
  • 41
    Spangler L, Ott SM, Scholes D. Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures. Osteoporos Int. 2011; 22:25237.
  • 42
    Narongroeknawin P, Patkar NM, Shakoory B, Jain A, Curtis JR, Delzell E, Lander PH, Lopez-Ben RR, Pitt MJ, Safford MM, Volgas DA, Saag KG. Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. J Clin Densitom. 2012; 15:92102.
  • 43
    Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly 1996–2007. J Bone Miner Res. 2011; 26:55360.
  • 44
    Abrahamsen B. Atypical femur fractures: refining the clinical picture. J Bone Miner Res. 2012; 27:9756.
  • 45
    Feldstein AC, Black D, Perrin N, Rosales AG, Friess D, Boardman D, Dell R, Santora A, Chandler JM, Rix MM, Orwoll E. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res. 2012; 27:97786.
  • 46
    Lo JC, Huang SY, Lee GA, Khandelwal S, Provus J, Ettinger B, Gonzalez JR, Hui RL, Grimsrud CD. Clinical correlates of atypical femoral fracture. Bone. 2012; 51:1814.
  • 47
    Meier RPH, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012; 172:9306.
  • 48
    Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364:172837.
  • 49
    Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br. 2012; 94:38590.
  • 50
    Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012; 27:254450.
  • 51
    Ng AC, Drake MT, Clarke BL, Sems SA, Atkinson EJ, Achenbach SJ, Melton LJ 3rd. Trends in subtrochanteric, diaphyseal, and distal femur fractures, 1984–2007. Osteoporos Int. 2012; 23:17216.
  • 52
    Maravic M, Ostertag A, Cohen-Solal M. Subtrochanteric/femoral shaft versus hip fractures: Incidences and identification of risk factors. J Bone Miner Res. 2012 Jan; 27(1):1307.
  • 53
    Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int. 2013 Feb; 24(2):70711.
  • 54
    Girgis CM, Seibel MJ. Bisphosphonate use and femoral fractures in older women. JAMA. 2011; 305:2068; author reply 2069.
  • 55
    Shkolnikova J, Flynn J, Choong P. Burden of bisphosphonate-associated femoral fractures. ANZ J Surg. 2013 Mar; 83(3):17581.
  • 56
    Adams AL, Shi J, Takayanagi M, Dell RM, Funahashi TT, Jacobsen SJ. Ten-year hip fracture incidence rate trends in a large California population, 1997–2006. Osteoporos Int. 2013 Jan; 24(1):3736.
  • 57
    Warren C, Gilchrist N, Coates M, Frampton C, Helmore J, McKie J, Hooper G. Atypical subtrochanteric fractures, bisphosphonates, blinded radiological review. ANZ J Surg. 2012; 82:90812.
  • 58
    La Rocca Vieira R, Rosenberg ZS, Allison MB, Im SA, Babb J, Peck V. Frequency of incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy. AJR Am J Roentgenol. 2012; 198:114451.
  • 59
    Powell D, Bowler C, Roberts T, Garton M, Matthews C, McCall I, Davie M. Incidence of serious side effects with intravenous bisphosphonate: a clinical audit. QJM. 2012; 105:96571.
  • 60
    Kim YS, Park WC. Atypical subtrochanteric femur fracture in patient with metastatic breast cancer treated with zoledronic Acid. J Breast Cancer. 2012; 15:2614.
  • 61
    Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. Epub. 2013 Feb13. DOI: 10.1002/jbmr.1893
  • 62
    Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int. 2011 Dec; 22(12):295161. Erratum in Osteoporos Int. 2012 Feb;23(2):793.
  • 63
    van der Meulen MC, Boskey AL. Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality. Arthritis Res Ther. 2012; 14:220.
  • 64
    Sutton RA, Mumm S, Coburn SP, Ericson KL, Whyte MP.Atypical femoral fractures” during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res. 2012; 27:987994.
  • 65
    Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res. 2009; 24:11324.
  • 66
    Yates CJ, Bartlett MJ, Ebeling PR. An atypical subtrochanteric femoral fracture from pycnodysostosis: a lesson from nature. J Bone Miner Res. 2011; 26:13779.
  • 67
    Birmingham P, McHale KA. Case reports: treatment of subtrochanteric and ipsilateral femoral neck fractures in an adult with osteopetrosis. Clin Orthop Relat Res. 2008; 466:20028.
  • 68
    Kumbaraci M, Karapinar L, Incesu M, Kaya A. Treatment of bilateral simultaneous subtrochanteric femur fractures with proximal femoral nail antirotation (PFNA) in a patient with osteopetrosis: case report and review of the literature. J Orthop Sci. 2013 May; 18(3):4869.
  • 69
    Sonohata M, Okubo T, Ono H, Mawatari M, Hotokebuchi T. Bipolar hip arthroplasty for subtrochanteric femoral nonunion in an adult with autosomal dominant osteopetrosis type II. J Orthop Sci. 2011; 16:6525.
  • 70
    Burr D, Milgrom C. Musculoskeletal fatigue and stress fractures. Boca Raton, FL: CRC Press; 2001.
  • 71
    Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17:12314.
  • 72
    Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011; 17:123541.
  • 73
    Ahlman MA, Rissing MS, Gordon L. Evolution of bisphosphonate-related atypical fracture retrospectively observed with DXA scanning. J Bone Miner Res. 2012; 27:4968.
  • 74
    McKiernan FE. Atypical femoral diaphyseal fractures documented by serial DXA. J Clin Densitom. 2010; 13:1023.
  • 75
    Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009; 80:4135.
  • 76
    Clement DB, Ammann W, Taunton JE, Lloyd-Smith R, Jesperson D, McKay H, Goldring J, Matheson GO. Exercise-induced stress injuries to the femur. Int J Sports Med. 1993; 14:34752.
  • 77
    Deutsch AL, Coel MN, Mink JH. Imaging of stress injuries to bone. Radiography, scintigraphy, and MR imaging. Clin Sports Med. 1997; 16:27590.
  • 78
    Ivkovic A, Bojanic I, Pecina M. Stress fractures of the femoral shaft in athletes: a new treatment algorithm. Br J Sports Med. 2006; 40:51820; discussion 520.
  • 79
    Spitz DJ, Newberg AH. Imaging of stress fractures in athletes. Radiol Clin North Am. 2002; 40:31331.
  • 80
    Donnelly E, Meredith DS, Nguyen JT, Gladnick BP, Rebolledo BJ, Shaffer AD, Lorich DG, Lane JM, Boskey AL. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res. 2012; 27:6728.
  • 81
    Koh JS, Goh SK, Png MA, Ng AC, Howe TS. Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singapore Med J. 2011; 52:7780.
  • 82
    Güerri-Fernández RC, Nogués X, Quesada Gómez JM, Torres Del Pliego E, Puig L, García-Giralt N, Yoskovitz G, Mellibovsky L, Hansma PK, Díez-Pérez A. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res. 2013; 28:1628.
  • 83
    Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008; 93:294852.
  • 84
    Jamal SA, Dion N, Ste-Marie LG. Atypical femoral fractures and bone turnover. N Engl J Med. 2011; 365:12612.
  • 85
    MacDonald MM, Schindeler A, Little DG. Bisphosphonate treatment and fracture repair. BoneKey. 2007; 4:23651.
  • 86
    Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab. 2009; 27:66372.
  • 87
    Allen MR, Kubek DJ, Burr DB, Ruggiero SL, Chu TM. Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs. Osteoporos Int. 2011; 22:693702.
  • 88
    Altundal H, Guvener O. The effect of alendronate on resorption of the alveolar bone following tooth extraction. Int J Oral Maxillofac Surg. 2004; 33:28693.
  • 89
    Chisin R. The role of various imaging modalities in diagnosing stress fractures. In: Burr DB, Milgrom C, editors. Musculoskeletal fatigue and stress fractures. Boca Raton, FL: CRC Press; 2001:27994.
  • 90
    Dell RM, Greene D, Tran D. Stopping bisphosphonate treatment decreases the risk of having a second atypical femur fracture. Paper presented at: American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting; 2012 Feb 7–11; San Francisco, CA, USA.
  • 91
    Crossley K, Bennell KL, Wrigley T, Oakes BW. Ground reaction forces, bone characteristics, and tibial stress fracture in male runners. Med Sci Sports Exerc. 1999; 31:108893.
  • 92
    Saita Y, Ishijima M, Mogami A, Kubota M, Kaketa T, Miyagawa K, Nagura N, Wada T, Sato T, Fukasaku S, Gen H, Obayashi O, Nemoto M, Kaneko K. Association between the fracture site and the mechanical axis of lower extremities in patients with atypical femoral fracture. J Bone Miner Res. 2012; 27(Suppl 1). Available from:
  • 93
    Sasaki S, Miyakoshi N, Hongo M, Kasukawa Y, Shimada Y. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. J Bone Miner Metab. 2012; 30:5617.
  • 94
    Koeppen VA, Schilcher J, Aspenberg P. Atypical fractures do not have a thicker cortex. Osteoporos Int. 2012; 23:28936.
  • 95
    Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaelsson K, Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone. 2013; 52:38992.
  • 96
    Sah AP, Thornhill TS, Leboff MS, Glowacki J. Correlation of plain radiographic indices of the hip with quantitative bone mineral density. Osteoporos Int. 2007; 18:111926.
  • 97
    Wernecke G, Namduri S, Dicarlo EF, Schneider R, Lane J. Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSS J. 2008; 4:1237.
  • 98
    Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011; 96:162732.
  • 99
    Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011; 96:267580.
  • 100
    Huang HT, Kang L, Huang PJ, Fu YC, Lin SY, Hsieh CH, Chen JC, Cheng YM, Chen CH. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report. Menopause. 2012; 19:13603.
  • 101
    Reddy SV, Gupta SK. Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence?. Singapore Med J. 2012; 53:e524.
  • 102
    Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, García-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010; 25:40414.
  • 103
    Mastaglia S, Aguilar G, Rossi E. Rapid resolution with teriparatide in delayed healing of atypical fracture associated to long- term bisphosphonate use. J Bone Miner Res. 2012; 27(Suppl 1). Available from:
  • 104
    Bock O, Felsenberg D. Atypical subtrochanteric and diaphyseal femoral fractures associated with long-term bisphosphonate use in postmenopausal osteoporosis—a case study. J Bone Miner Res. 2012; 27(Suppl 1). Available from:
  • 105
    Cheung AM, Bleakney R, Kahn A, et al. Effect of teriparatide on fracture healing in patients with non-displaced incomplete atypical femur fractures. J Bone Miner Res. 2012; 27(Suppl 1). Available from:
  • 106
    Miller PD, McCarthy E. Quantitative bone histomorphometry in patients with bisphosphonate-associated atypical subtrochanteric femur fractures before and after 12 months of teriparatide. J Bone Miner Res. 2012; 12(Suppl 1). Available from:
  • 107
    Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013; 52:3605.